131 related articles for article (PubMed ID: 38134481)
1. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
Postmus D; Litiere S; Bogaerts J; Versluis J; Cornelissen JJ; Pignatti F
Eur J Cancer; 2024 Jan; 197():113496. PubMed ID: 38134481
[TBL] [Abstract][Full Text] [Related]
2. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
3. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
4. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.
Raphael MJ; Robinson A; Booth CM; O'Donnell J; Palmer M; Eisenhauer E; Brundage M
JAMA Oncol; 2019 Dec; 5(12):1779-1789. PubMed ID: 31556921
[TBL] [Abstract][Full Text] [Related]
5. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival.
Brundage MD; Booth CM; Eisenhauer EA; Galica J; Kankesan J; Karim S; Koven R; McDonald V; Ng T; O'Donnell J; Ten Hove J; Robinson A
J Natl Cancer Inst; 2023 Dec; 115(12):1526-1534. PubMed ID: 37458509
[TBL] [Abstract][Full Text] [Related]
6. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
Llovet JM; Montal R; Villanueva A
J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract][Full Text] [Related]
8. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
9. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
He Q; Li Q; Lv F; Kaitin KI; Shao L
Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
[TBL] [Abstract][Full Text] [Related]
10. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
[TBL] [Abstract][Full Text] [Related]
11. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
12. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
13. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
[TBL] [Abstract][Full Text] [Related]
14. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival in oncology: Caveat emptor!
Bergmann TK; Christensen MMH; Henriksen DP; Haastrup MB; Damkier P
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):240-244. PubMed ID: 30417586
[TBL] [Abstract][Full Text] [Related]
17. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
18. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Michiels S; Saad ED; Buyse M
Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
